Good-quality research in rare diseases: trials and tribulations

Pediatric Nephrology

Volumn 31, Issue 11, 2016, Pages 2017-2023

  Bolignano, Davide ^a   Pisano, Anna ^a  

^a CNR Institute of Clinical Physiology   (Italy)

Author keywords

Clinical guidelines; Clinical trials; Orphan diseases; Rare diseases

Indexed keywords

EVIDENCE BASED PRACTICE; GOOD CLINICAL PRACTICE; HUMAN; INTERVENTION STUDY; KIDNEY DISEASE; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); ADULT; EVIDENCE BASED MEDICINE; METHODOLOGY; PATIENT SELECTION; PREVALENCE; STANDARDS;

ADULT; BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY DISEASES; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84955598295     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-016-3323-7     Document Type: Review

References (22)

1. (1984 as amended) Orphan Drug Act, Public Law, No. 97-414, 96 Statute 2049. Available at https://www.gpo.gov/fdsys/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf
2. (2013) National Center for Advancing Translational Sciences. Office of Rare Disease Research. Frequently asked questions. https://rarediseases.info.nih.gov/about-gard/pages/31/frequently-asked-questions. Accessed 26 October 2015
3. (2005) EURORDIS: European Organisation for Rare Diseases. Rare disease: understanding this public health priority. http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed 26 October 2015
4. Research, N.I.o.H.O.o.R.D. http://rarediseases.info.nih.gov. Accessed 26 October 2015
5. Soliman NA (2012) Orphan kidney diseases. Nephron Clin Pract 120:c194–c199
6. (2009) Report, U.S.R.D.S. http:// www.usrds.org. Accessed 26 October 2015
7. NICE National Institute for Health and Care Excellence. https://www.nice.org.uk. Accessed 26 October 2015
8. Bolignano D, Nagler EV, Van Biesen W, Zoccali C (2014) Providing guidance in the dark: rare renal diseases and the challenge to improve the quality of evidence. Nephrol Dial Transplant 29:1628–1632
9. (EMEA) (2007) E.M.A. Guideline on clinical trials in small populations. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf. Accessed 26 October 2015
10. Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS (2014) Innovative research methods for studying treatments for rare diseases: methodological review. BMJ 349:g6802
11. Schulz KF, Grimes DA (2005) Sample size calculations in randomised trials: mandatory and mystical. Lancet 365:1348–1353
12. van der Lee JH, Wesseling J, Tanck MW, Offringa M (2008) Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J Clin Epidemiol 61:324–330
13. Shurin S, Krischer J, Groft SC (2012) Clinical trials In BMT: ensuring that rare diseases and rarer therapies are well done. Biol Blood Marrow Transplant 18:S8–S11
14. Buckley BM (2008) Clinical trials of orphan medicines. Lancet 371:2051–2055
15. Wolterbeek R (1994) One and two sided tests of significance. BMJ 309:873–874
16. Gimpel C, Wuhl E, Arbeiter K, Drozdz D, Trivelli A, Charbit M, Gellermann J, Dusek J, Jankauskiene A, Emre S, Schaefer F, Group ET (2009) Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials. J Hypertens 27:1568–1574
17. Zhu H, Zhang S, Ahn C (2015) Sample size considerations for historical control studies with survival outcomes. J Biopharm Stat. doi:10.1080/10543406.2015.1052495
18. Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P, Cresim ECPG, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassai B, Nony P, Ogungbenro K, Perol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R (2013) Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis 8:48
19. Rochon J (1990) A statistical model for the “N-of-1” study. J Clin Epidemiol 43:499–508
20. Chow SC, Chang M (2008) Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 3:11
21. Sebille V, Bellissant E (2003) Sequential methods and group sequential designs for comparative clinical trials. Fundam Clin Pharmacol 17:505–516
22. Tan SB, Dear KB, Bruzzi P, Machin D (2003) Strategy for randomised clinical trials in rare cancers. BMJ 327:47–49